Can CAR-T Cells Treat an Incurable Childhood Brain Cancer? A 2024 Trial

Few diagnoses are as heartbreaking as diffuse midline glioma — often called DIPG when it sits in the brainstem. It strikes mainly children, sits in places too dangerous to remove surgically, and has resisted almost every treatment tried against it, with survival usually measured in months. So a 2024 trial reporting that CAR-T cells could shrink these tumours is genuinely significant — and exactly the kind of result that deserves both hope and a clear head ¹.

This is, in the most literal sense, promising research: an early trial in a cancer where almost nothing has worked before. Reading it honestly means honouring both the breakthrough and its limits.

What question did the researchers ask?

A team at Stanford asked whether CAR-T cells engineered to target a molecule called GD2 — which is found at high levels on diffuse midline glioma cells — could be given safely to patients with these tumours, and whether there were signs of benefit ¹.

The delivery strategy was the clever part. Patients first received GD2 CAR-T cells intravenously (into a vein), and then, in those who tolerated it, directly into the brain through repeated intracranial infusions. The idea was to combine a body-wide dose with a localised one delivered right where the tumour lives — addressing the long-standing problem that CAR-T cells given into the blood often can't reach brain tumours. If CAR-T is unfamiliar, our overview of CAR-T therapy explains the basics.

What did the trial find?

This was a small phase 1 trial — 13 patients enrolled and 11 treated — designed mainly to test safety. Within those limits, the results were striking for this disease.

The therapy produced tumour regressions and neurological improvements in several patients — meaning some children regained function they had been losing, which in DMG is remarkable. And crucially, some participants were alive two or more years after treatment, far longer than typically expected with this cancer ¹. In a disease that almost no one survives, those are extraordinary signals, even from a small trial.

The therapy was not without serious risk. Targeting the brain with activated immune cells can cause inflammation and neurological side effects, which required careful management in an expert centre. This is intensive, high-stakes treatment — not a gentle intervention.

How strong is this evidence?

It's early-phase evidence, and that framing is essential. Eleven treated patients cannot establish how often the therapy helps, how long benefits last, or whether it will succeed in larger, more diverse groups. Phase 1 trials are stepping stones — they show an approach is worth pursuing, not that it's proven.

But context matters too. In a cancer with a near-zero survival rate and decades of failed treatments, any reproducible tumour regression and multi-year survival is a meaningful scientific signal. The result has rightly energised the field and supports moving toward larger trials. The honest reading is "a real breakthrough in early research", not "a cure is here".

What could this mean if you are considering treatment?

For families facing DMG or DIPG, this trial is a genuine reason for hope — and a reason to seek out specialist centres and clinical trials, because that is where this therapy currently exists. It is not an approved, off-the-shelf treatment, and the risks demand expert neuro-oncology care.

The useful questions to ask a treating team: Are there open GD2 CAR-T (or similar) trials my child might qualify for? What does the treatment and monitoring involve? What are the realistic goals — controlling the tumour, improving symptoms, gaining time? Be wary of any clinic promising this therapy as a guaranteed cure, which the evidence does not support.

What we see at the clinic

Childhood brain cancers are not something we treat, but families do sometimes ask us how to make sense of headlines like this one. Our role is honesty: results like this are a real and moving advance, the product of careful science, and the right path is reputable trials and specialist teams — not unproven "cell therapy" sold as a sure thing. We'd always rather help a family find legitimate hope than fall for false certainty.

Common questions

Is this a cure for DIPG/DMG? No. It's an early-phase trial showing tumour shrinkage and longer survival in some of 11 treated patients ¹ — a major signal in a near-untreatable cancer, but not a proven cure.

Is GD2 CAR-T widely available? No. It's experimental and offered through specialist clinical trials, not as a standard treatment.

Why give the cells both into a vein and into the brain? To combine a body-wide dose with one delivered directly to the tumour, since CAR-T cells in the bloodstream often struggle to reach brain cancers.

[1] Intravenous and intracranial GD2-CAR T cells for H3K27M+ diffuse midline gliomas. Nature. 2024. https://doi.org/10.1038/s41586-024-08171-9

Key takeaway

In a small 2024 trial, GD2 CAR-T cells shrank tumours and improved symptoms in several children with diffuse midline glioma, with some surviving two or more years — extraordinary in a cancer that almost no one survives. It's early-phase and risky, not a finished cure, but it's one of the most hopeful recent signals in paediatric brain cancer and a strong reason for larger trials.